Search research articles
Contact Us
Filters
Showing results (71-80 of 102) with videos related to
Page
of 11
Sort By:
British Journal of Haematology
|
November 20, 2018
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Hartmut Döhner, Carsten Müller-Tidow, Michael Lübbert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 26, 2006
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Junya Kuroda, Hamsa Puthalakath, Mark S Cragg, et al.
Annals of Hematology
|
August 28, 2013
Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia
Gesine Bug, Steffen Koschmieder, Juergen Krauter, et al.
Haematologica
|
January 14, 2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, et al.
Experimental Hematology
|
January 13, 2009
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors
Bart A Nijmeijer, Karoly Szuhai, Henriëtte M Goselink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2003
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate
Heike Pfeifer, Barbara Wassmann, Wolf-Karsten Hofmann, et al.
Cancer
|
March 27, 2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
Ruth Seggewiss-Bernhardt, Ralf C Bargou, Yeow Tee Goh, et al.
Haematologica
|
March 28, 2008
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
Paul La Rosée, Susanne Holm-Eriksen, Heiko Konig, et al.
British Journal of Haematology
|
September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
Carsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
American Journal of Hematology
|
February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 102) with videos related to
Sort By:
Page
of 11
British Journal of Haematology
|
November 20, 2018
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Hartmut Döhner, Carsten Müller-Tidow, Michael Lübbert, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 26, 2006
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Junya Kuroda, Hamsa Puthalakath, Mark S Cragg, et al.
Annals of Hematology
|
August 28, 2013
Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia
Gesine Bug, Steffen Koschmieder, Juergen Krauter, et al.
Haematologica
|
January 14, 2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, et al.
Experimental Hematology
|
January 13, 2009
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors
Bart A Nijmeijer, Karoly Szuhai, Henriëtte M Goselink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2003
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate
Heike Pfeifer, Barbara Wassmann, Wolf-Karsten Hofmann, et al.
Cancer
|
March 27, 2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
Ruth Seggewiss-Bernhardt, Ralf C Bargou, Yeow Tee Goh, et al.
Haematologica
|
March 28, 2008
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
Paul La Rosée, Susanne Holm-Eriksen, Heiko Konig, et al.
British Journal of Haematology
|
September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
Carsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
American Journal of Hematology
|
February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Page
of 11